Vancomycin for Allergies

This trial explores how vancomycin, administered through infusion, affects individuals without traditional allergy markers. Researchers aim to identify new blood markers that emerge during a reaction to the drug. The study targets generally healthy individuals who have never taken vancomycin and do not have certain medical conditions, such as allergies to similar drugs or ongoing infections. Participants will undergo a skin allergy test for vancomycin and receive a single infusion of the drug. As a Phase 1 trial, the research focuses on understanding the treatment's effects in people, offering participants an opportunity to contribute to groundbreaking research.

You will need to stop taking antihistamines one week before joining the study and cannot take them during the trial. If you are using beta-blockers, immunomodulatory therapies, oral corticosteroids, or biologics, you may not be eligible to participate.

Research has shown that vancomycin, an antibiotic, can cause different reactions in some people. In a large study, about 0.3% of patients reported an allergy or sensitivity to vancomycin. This means that out of over 4 million patients, only a small number experienced some kind of reaction.

The most common reaction is a vancomycin infusion reaction (VIR), occurring in 3.7% to 47% of people receiving the drug. VIR can cause symptoms like skin redness and itching. In rare cases, more serious reactions like anaphylaxis, a severe allergic reaction, have occurred, but these are less common.

Vancomycin is unique because it is being explored as an unconventional treatment for allergies, which is different from the usual antihistamines and corticosteroids. Typically used as an antibiotic, vancomycin's potential lies in its ability to modulate the microbiome, which might influence allergic responses. Researchers are excited about this approach because it targets the underlying microbiological factors, offering a fresh perspective on allergy management.

Research has shown that vancomycin can cause various unexpected allergic reactions, known as hypersensitivity reactions. These reactions may occur immediately or take time to appear, with about 42% of cases showing immediate signs. The most common reaction is the vancomycin infusion reaction (VIR), occurring in up to 47% of patients. However, many patients (about 86%) who exhibit symptoms do not have a true allergy, meaning their reactions are not immune system-related. This trial will involve a single infusion of vancomycin in healthy volunteers to study these reactions. Identifying specific biomarkers, detectable signs in the blood, during these reactions is crucial for understanding how and why they occur. This could help doctors determine who might experience these reactions and how to prevent them.¹²³⁴⁶